These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 39043643)
1. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity. Ye QN; Zhu L; Liang J; Zhao DK; Tian TY; Fan YN; Ye SY; Liu H; Huang XY; Cao ZT; Shen S; Wang J Nat Commun; 2024 Jul; 15(1):6211. PubMed ID: 39043643 [TBL] [Abstract][Full Text] [Related]
9. Purinergic targeting enhances immunotherapy of CD73 Wang J; Lupo KB; Chambers AM; Matosevic S J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403 [TBL] [Abstract][Full Text] [Related]
10. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Kim N; Kim HS Front Immunol; 2018; 9():2041. PubMed ID: 30250471 [TBL] [Abstract][Full Text] [Related]
11. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
12. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037 [TBL] [Abstract][Full Text] [Related]
13. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Maniar A; Zhang X; Lin W; Gastman BR; Pauza CD; Strome SE; Chapoval AI Blood; 2010 Sep; 116(10):1726-33. PubMed ID: 20519625 [TBL] [Abstract][Full Text] [Related]
16. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866 [TBL] [Abstract][Full Text] [Related]
17. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry. Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817 [TBL] [Abstract][Full Text] [Related]
18. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669 [TBL] [Abstract][Full Text] [Related]
19. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8 Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591 [TBL] [Abstract][Full Text] [Related]
20. TIGIT-Fc Promotes Antitumor Immunity. Shen X; Fu W; Wei Y; Zhu J; Yu Y; Lei C; Zhao J; Hu S Cancer Immunol Res; 2021 Sep; 9(9):1088-1097. PubMed ID: 34244300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]